How many insider trades does FilingIQ track for ARQT?

FilingIQ tracks 652 Form 4 insider transactions for ARQT (Arcutis Biotherapeutics, Inc.), covering filings from Feb 3, 2020 onwards. 37 of those were filed in the last 90 days.

Are ARQT insiders net buyers or net sellers?

Across the full Form 4 history for ARQT, 29 transactions (4%) were open-market purchases and 331 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ARQT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ARQT in?

Arcutis Biotherapeutics, Inc. (ARQT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.17B.

ARQT insider trading

Healthcare

Arcutis Biotherapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

652

Last 90 days

Buys / sells

4% / 51%

Market cap

$3.17B

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Company website: www.arcutis.com

ARQT insider activity at a glance

FilingIQ has scored 652 insider transactions for ARQT since Feb 3, 2020. The most recent filing in our index is dated May 11, 2026.

Across the full history, 29 open-market purchases and 331 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ARQT insider trades is 58.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ARQT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ARQT

Frazier Life Sciences Management, L.P.

$128.53M · 8.0% of AUM

Rubric Capital Management LP

$26.73M · 1.0% of AUM

STEMPOINT CAPITAL LP

$8.98M · 2.6% of AUM

Frequently asked

How many insider trades does FilingIQ track for ARQT?: FilingIQ tracks 652 Form 4 insider transactions for ARQT (Arcutis Biotherapeutics, Inc.), covering filings from Feb 3, 2020 onwards. 37 of those were filed in the last 90 days.
Are ARQT insiders net buyers or net sellers?: Across the full Form 4 history for ARQT, 29 transactions (4%) were open-market purchases and 331 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ARQT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ARQT in?: Arcutis Biotherapeutics, Inc. (ARQT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.17B.

Methodology & sources

Every ARQT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.